Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.77 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.62 |
| ▸ | HPGD | P15428 | 4/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.62 |
| ▸ | MEN1 | O00255 | 3/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | USP2 | O75604 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20985659 | 0.98 | ATM (0.74) | ATML3MBTL1KMT2AHPGDTDP1 | |
| SCHEMBL4865397 | 0.96 | ATM (0.71) | ATML3MBTL1KMT2AHPGDTDP1 | |
| SCHEMBL10590320 | 0.94 | ATM (0.68) | ATML3MBTL1KMT2AHPGDTDP1 | |
| SCHEMBL9699192 | 0.94 | ATM (0.68) | ATML3MBTL1KMT2AHPGDTDP1 | |
| SCHEMBL11408812 | 0.94 | ATM (0.68) | ATML3MBTL1KMT2AHPGDTDP1 | |
| SCHEMBL10590368 | 0.92 | ATM (0.65) | ATML3MBTL1KMT2AHPGDTDP1 | |
| SCHEMBL20985713 | 0.88 | ALDH1A1 (0.81) | ATML3MBTL1KMT2AHPGDTDP1 | |
| SCHEMBL16093106 | 0.86 | ALDH1A1 (0.77) | ATML3MBTL1KMT2AHPGDTDP1 | |
| SCHEMBL6927269 | 0.86 | MEN1 (0.70) | ATML3MBTL1KMT2AHPGDTDP1 | |
| SCHEMBL28366947 | 0.85 | ATM (0.85) | ATML3MBTL1KMT2AHPGDTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11725000-B2 | Apoptosis inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2023-08-15 | — | — | US | disclosed |
| CN-110023292-B | Apoptosis inhibitors | 北京生命科学研究所 | 2022-10-04 | — | — | CN | disclosed |
| US-20210309647-A1 | Apoptosis Inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2021-10-07 | — | — | US | disclosed |
| US-11034680-B2 | Apoptosis inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2021-06-15 | — | — | US | disclosed |
| EP-3484854-B1 | APOPTOSIS INHIBITORS | NAT INSTITUTE OF BIOLOGICAL SCIENCES BEIJING (CN) | 2021-01-20 | — | — | EP | disclosed |
| US-20190152960-A1 | Apoptosis Inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2019-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190152960-A1 | Apoptosis Inhibitors | BAX, SDHA, SDHB | ATM 1013/4885L3MBTL1 1858/4885KMT2A 3060/4885 |
| US-11725000-B2 | Apoptosis inhibitors | BAX, SDHA, SDHB | ATM 1013/4885L3MBTL1 1858/4885KMT2A 3060/4885 |
| US-11034680-B2 | Apoptosis inhibitors | BAX, SDHA, SDHB | ATM 1013/4885L3MBTL1 1858/4885KMT2A 3060/4885 |
| US-20210309647-A1 | Apoptosis Inhibitors | BAX, SDHA, SDHB | ATM 1013/4885L3MBTL1 1858/4885KMT2A 3060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.